LC/MS分析大鼠体内氧化苦参碱及其主要代谢物LC/MS分析大鼠体内氧化苦参碱及其主要代谢物

目的研究氧化苦参碱在大鼠体内的主要代谢产物。方法以氧化苦参碱和苦参碱为对象优化液相色谱/电喷雾离子阱质谱(LC/ESI-ITMSⁿ)实验条件，分析总结其电喷雾质谱的一级电离规律和二级质谱裂解规律，作为氧化苦参碱大鼠体内代谢物结构分析的依据。健康大鼠腹腔肌注40 mg·kg^-1氧化苦参碱，收集0~24 h的尿样，尿样中的代谢物经C₁₈小柱进行富集与纯化后，在优化的LC/ESI-ITMSⁿ条件下进样分析。代谢物的结构推导主要依据代谢物的色谱保留时间及其电喷雾离子阱质谱(ESI-ITMSⁿ)电离规律。结果在大鼠尿样中有原药及其6种I相氧化及还原代谢产物，且主要代谢物为苦参碱。未发现II相代谢物。结论本法不仅操作简便、快速，而且灵敏度高、专属性强。该分析技术是研究药物代谢最有效的方法之一。     

高效液相色谱-电喷雾离子阱串联质谱分析水苏碱及其大鼠体内代谢物

目的鉴定水苏碱在大鼠体内的代谢物。方法应用高效液相色谱-电喷雾离子阱串联质谱(HPLC-ESI/MSⁿ)技术研究水苏碱的一级质谱电离规律、二级质谱裂解规律及其色谱保留，以此作为水苏碱大鼠体内代谢物分析鉴定的依据；再将健康大鼠空腹灌胃25 mg·kg^-1水苏碱，收集0～24 h的尿样，经C₁₈小柱固相萃取分离纯化后，应用HPLC-ESI/MS分析尿样中水苏碱代谢物。结果在大鼠尿样中发现了母药及其N-去甲基、氧化脱氢、环氧化等6种I相代谢产物及两种环氧化物的甘氨酸轭合II相代谢产物。结论HPLC-ESI/MS法灵敏度高，快速，定性能力强，适合于水苏碱大鼠体内代谢物的分析。     

HPLC-ESI-ITMSn法鉴定麻黄碱及其大鼠体内主要代谢产物

目的建立快速灵敏的LC-ESI-ITMSⁿ分析检测麻黄碱及其大鼠体内代谢物的方法。方法以麻黄碱对照品对LC-ESI-ITMS²色谱及质谱条件进行了优化，分析总结其电喷雾质谱的一级电离规律和多级质谱裂解规律，以此作为麻黄碱大鼠体内代谢物分析鉴定的依据。健康大鼠空腹灌胃麻黄碱10 mg·kg^-1，收集0~48 h的尿样，经C₁₈小柱固相萃取分离纯化后，直接采用LC-ESI-ITMSⁿ方法对尿样进行测定。结果根据生物体内药物代谢转化规律及母体药物的色谱-质谱行为规律，在尿样中鉴定出3个第I相代谢产物，未发现第II相代谢产物。结论本方法灵敏、快速、选择性高、专属性好，可用于麻黄碱的代谢产物研究。     

液相色谱-串联电喷雾离子阱质谱法鉴定大鼠尿液中药根碱代谢物

目的研究药根碱在大鼠体内的主要代谢产物。方法健康大鼠尾静脉注射12 mg·kg^-1药根碱，收集0～72 h的尿样，尿样经C₁₈小柱固相萃取分离纯化后，经液相色谱-串联电喷雾离子阱质谱(LC-ESI/ITMSⁿ)分析鉴定其中的代谢物。代谢物的结构鉴定主要依据各代谢物与原药的一级质谱电离规律和二级或三级质谱裂解规律间的关联性。结果在大鼠尿样中检测到7种I相代谢产物(如原药的脱氢、脱甲基、羟基化代谢物)及11种II相代谢产物(如甲基化轭合物和葡糖醛酸轭合物)。结论本方法用于大鼠尿样中药根碱的代谢物研究不仅操作简单、快速，而且灵敏度高、专属性强。     

罂粟碱的体内与体外代谢物研究

利用HPLC-MSⁿ检测罂粟碱及其在大鼠体内(大鼠粪便)和体外(肝微粒体, 肠道菌)代谢物。体内与体外的代谢物经C₁₈小柱进行富集和纯化后, 直接采用优化的HPLC-ESI/ITMSⁿ方法对样品进样分析。以罂粟碱标准品为对象优化高效液相色谱/电喷雾离子阱质谱(HPLC-ESI/ITMSⁿ )实验条件, 分析总结其电喷雾质谱的一级电离规律和多级质谱裂解规律, 作为罂粟碱大鼠体内与体外代谢物结构分析的依据。代谢物的结构推导主要依据代谢物的色谱保留时间及其电喷雾离子阱质谱HPLC-ESI/ITMSⁿ电离规律。在大鼠粪便中有原药及其8种代谢产物。体外代谢物检测到原药的脱甲基和羟基化。     

HPLC-MSn法鉴定葫芦巴碱及其在大鼠体内的主要代谢产物

目的建立快速灵敏的LC-MSⁿ检测葫芦巴碱及其在大鼠体内代谢物的分析方法。方法以葫芦巴碱对LC-MS²色谱及质谱条件进行优化，分析其电喷雾质谱的一级电离规律和多级质谱裂解规律，以此作为葫芦巴碱大鼠体内代谢物分析鉴定的依据。健康大鼠尾静脉注射8 mg·kg^-1葫芦巴碱，收集0～48 h的尿样，经C₁₈小柱固相萃取分离纯化后，直接采用LC-MSⁿ方法对尿样进行测定。结果根据生物体内药物代谢转化规律及母体药物的色谱-质谱行为规律，在尿样中鉴定出母药及其N-去甲基、N-去甲基环氧化产物，以及母药及其N-去甲基环氧化物的甘氨酸轭合物。结论本方法灵敏、快速、选择性高、专属性好，可用于葫芦巴碱的代谢产物研究。     

液相色谱-串联质谱法分析抗肿瘤新药乙烷硒啉在大鼠体内的代谢产物

本研究对抗肿瘤新药1,2-[二(1,2-苯并异硒唑-3(2H)-酮)]乙烷(乙烷硒啉,BBSKE)在大鼠体内的代谢产物进行鉴定。在灌胃给予大鼠单剂量乙烷硒啉200mg·kg-1后,采用液相色谱-串联质谱法(LC-MSn)对大鼠尿液、粪样、胆汁和血浆中的代谢产物进行检测,通过全扫描和选择离子扫描,以及根据多级质谱裂解规律对代谢物的结构进行分析。研究发现在大鼠尿样、粪样、胆汁和血浆中检测到3种Ⅰ相代谢产物和1种Ⅱ相代谢产物,其代谢途径分别为氧化、甲基化、硫甲基化和葡萄糖醛酸化反应,提示乙烷硒啉在大鼠体内的代谢方式可能是通过氧化、甲基化及葡萄糖醛酸化反应形成代谢产物。     

液相色谱-串联电喷雾离子阱质谱法鉴定大鼠尿液中大豆黄素的羟基化代谢产物及其硫酸酯轭合物

目的鉴定大豆黄素在大鼠体内的羟基化及其结合形代谢产物。方法SD大鼠分别单剂量给药500 mg·kg^-1，收集0～24 h尿样。尿样经SPE ODS C₁₈固相萃取柱纯化后，用LC-ESI/MSⁿ对尿样中的代谢物分别进行选择离子监测(SIM)和多级质谱(MSⁿ)分析。结果在大鼠尿中检测到几种尚未在国内外报道过的羟基化代谢产物及其硫酸酯轭合物。结论LC-ESI/MSⁿ法可以快速、简捷、准确地鉴定大豆黄素在大鼠体内羟基化及其结合形代谢产物。     

液相色谱-电喷雾离子阱质谱法分析大鼠血浆中的樟柳碱及其代谢物

目的用液相色谱-电喷雾离子阱串联质谱(LC-MS^{n)联用方法鉴定大鼠血浆中的樟柳碱及其主要代谢物。方法取单剂量灌胃樟柳碱20 mg的大鼠血浆，甲醇沉淀蛋白，采用LC-MSn等方法分析血样。与空白血样及樟柳碱对照品相比较，根据血样中代谢物相对分子质量的变化及其多级质谱数据，鉴定并阐述其结构。结果在服药后的大鼠血样中发现4种代谢物， 分别为东莨菪醇、 N-去甲基东莨菪醇、 羟基化樟柳碱以及N-氧化樟柳碱。结论 该方法灵敏、快速、简便，适合于药物及其代谢物的快速鉴定。}     

稳定同位素标记结合离子阱质谱鉴别大鼠尿中胍丁胺及其乙酰化代谢产物

目的：识别大鼠给予胍丁胺后尿中药物原形及其代谢产物，推测其可能的代谢途径。方法：采用同位素^2H标记药物，尿样经固相提取后利用液相色谱-电喷雾离子阱质谱进行分离检测，利用离子簇技术和离子阱MS^n技术对药物原形及其代谢产物进行识别。结果：在大鼠尿中检测到胍丁胺原形，并发现其乙酰化代谢产物，作者未见文献报道。结论：胍丁胺在大鼠尿中主要以原形和乙酰化产物2种途径排泄。     

Evaluation of the excretion, and metabolism of the cardiotonic agent bemoradan in male rats and female beagle dogs.

The excretion and metabolism of (+/-) [6-(3,4-dihydro-3-oxo-1,4[2H]-benzoxazine-yl)-2,3,4,5-tetrahydro-5-methylpyridazin-3-one] (bemoradan; RWJ-22867) have been investigated in male Long-Evans rats and female beagle dogs. Radiolabeled [14C] bemoradan was administered to rats as a singkle 1 mg/kg suspension dose while the dogs received 0.1 mg/kg suspension dose. Plasma (0-24 h; rat and dog), urine (0-72 h; rat and dog) and fecal (0-72 h; rat and dog) samples were collected and analyzed. The terminal half-life of the total radioactivity for rats from plasma was estimate to be 4.3 +/- 0.1 h while for dogs it was 7.5 +/- 1.3 h. Recoveries of total radioactivity in urine and feces for rats were 49.1 +/- 2.4% and 51.1 +/- 4.9% of th dose, respectively. Recoveries of total radioactivity in urine and feces for dogs were 56.2 +/- 12.0% and 42.7 V 9.9% of the dose, respectively. Bemoradan and a total of nine metabolites were isolated and tentatively identified in rat and dog plasma, urine, and fecal extracts. Unchanged bemoradan accounted for approimately < 2% of the dose in rat urine and 20% in rat feces. Unchanged bemoradan accounted for approximately 5% of the dose in urine and 16% in feces in dog. Six proposed pathways were used to describe the metabolites found in rats and dogs: pyridazinyl oxidations, methyl hydroxylation, hydration, N-oxidation, dehydration and phase II conjugations.     

Characterization of metabolites of worenine in rat biological samples using liquid chromatography–tandem mass spectrometry

The in vivo and in vitro metabolites of worenine in rat were identified or characterized using a specific and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. In vivo samples including rat urine, feces, and plasma samples were collected after ingestion of 25 mg/kg worenine to healthy rats. The in vivo and in vitro samples were cleaned up by a solid-phase extraction procedure (C18 cartridges) and a liquid–liquid extraction procedure, respectively. Then these pretreated samples were injected into a reversed-phase C18 column with mobile phase of methanol–ammonium acetate (2 mM, adjusted to pH 3.5 with formic acid) (60:40, v/v) and detected by an on-line MS/MS system. As a result, at least twenty-seven metabolites and the parent medicine were found in rat urine after ingestion of worenine. Seven metabolites and the parent medicine were identified or characterized in rat feces. Three metabolites and the parent medicine were detected in rat plasma. One metabolite was found in the rat intestinal flora incubation mixture, and three metabolites were characterized in the homogenized liver incubation mixture. The main phase I metabolism of worenine in rat was dehydrogenization, hydrogenation, hydroxylation, and demethylene reactions, and that of phase II was sulfation and glucuronidation.     

LC-MS/MS法研究1-[1-(6-甲氧基-2-萘基)乙基]-2-(4-硝基苄基)-6,7-二甲氧基-1,2,3,4-四氢异喹啉氢溴酸盐在大鼠体内的代谢产物

采用液相色谱-串联质谱法对大鼠灌胃1-［1-(6-甲氧基-2-萘基)乙基］-2-(4-硝基苄基)-6,7-二甲氧基-1,2,3,4-四氢异喹啉氢溴酸盐(编号P91024)后粪便、尿液、胆汁和血浆中的主要代谢产物进行研究。通过比较给药样品和空白样品的全扫描总离子流色谱和选择离子扫描色谱图差别寻找I相代谢产物；根据其一级和二级质谱图，确定I相代谢产物的分子结构。完全提取I相代谢产物后的样品溶液，再用葡糖醛酸酶酶解，得II相结合物的苷元部分，采用与I相代谢产物鉴定同样方法寻找和鉴定II相代谢产物苷元的结构，进而确证II相代谢产物的分子结构。从大鼠粪便中鉴定出P91024的2个I相代谢物，从胆汁中鉴定出1个I相和5个II相代谢产物，从尿液中鉴定出1个I相和3个II相代谢产物，从血浆中鉴定出4个I相和1个II相代谢产物；并分别分析推测出它们的结构。P91024在大鼠体内被代谢转化为多种产物，利用LC-MS/MS可以快速寻找和鉴定。     

Structural elucidation of in vivo and in vitro metabolites of anisodine by liquid chromatography-tandem mass spectrometry

Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESIMSn) was employed to investigate the in vivo and in vitro metabolism of anisodine. Feces, urine and plasma samples were collected after ingestion of 20 mg anisodine to healthy rats. Feces and urine samples were cleaned up by liquid-liquid extraction and solid-phase extraction procedures (C18 cartridges), respectively. Methanol was added to plasma samples to precipitate plasma proteins. Anisodine was incubated with homogenized liver and intestinal flora of rats in vitro, respectively, followed by extraction with ethyl acetate. LC-MSn was used for the separation and identification of the metabolites using C18 column with mobile phase of methanol/0.01% triethylamine solution (2 mM, adjusted to pH 3.5 with formic acid) (60:40, v/v). The results revealed that five metabolites (norscopine, scopine, alpha-hydroxytropic acid, noranisodine and hydroxyanisodine) and the parent drug existed in feces. Three new metabolites (dimethoxyanisodine, tetrahydroxyanisodine and trihydroxy-methoxyanisodine) were identified in urine. Four metabolites (norscopine, scopine, hydroxyanisodine and anisodine N-oxide) and the parent drug were detected in plasma. Two hydrolyzed metabolites (scopine and alpha-hydroxytropic acid) were found in rat intestinal flora incubation mixture, and two metabolites (aponoranisodine and anisodine N-oxide) were identified in homogenized liver incubation mixture.     

Evaluation of the absorption, excretion, and metabolism of the antihypertensive agent RWJ-26899 in male and female CR Wistar rats and Beagle dogs.

The absorption, excretion and metabolism of N-(2, 6-dichlorophenyl)-beta-[[(1-methylcyclohexyl)methoxylmethyl]-N-(phenylmethyl)-1-pyrrolidineethanamine (RWJ-26899; McN-6497) has been investigated in male and female CR Wistar rats and beagle dogs. Radiolabeled [14C] RWJ-26899 was administered to rats as a single 24 mg/kg suspension dose while the dogs received 15 mg/kg capsules. Plasma (0-36 h; rat and 0-48 h; dog), urine (0-192 h; rat and dog) and fecal (0-192 h; rat and dog) samples were collected and analyzed. There were no significant gender differences observed in the data. The terminal half-life of the total radioactivity for rats from plasma was estimated to be 7.7 +/- 0.6 h while for dogs it was 22.9 +/- 4.4 h. Recoveries of total radioactivity in urine and feces for rats were 8.7 +/- 2.9% and 88.3 +/- 10.4% of the dose, respectively. Recoveries of total radioactivity in urine and feces for dogs were 4.1 +/- 1.4% and 90.0 +/- 4.7% of the dose, respectively. RWJ-26899 and a total of nine metabolites were isolated and tentatively identified in rat urine, and fecal extracts. Unchanged RWJ-26899 accounted for approximately 1% of the dose in rat urine and 8% in rat feces. RWJ-26899 and a total of four metabolites were isolated and identified in dog urine, and fecal extracts. Unchanged RWJ-26899 accounted for approximately 1% of the dose in urine and 63% in feces in dog. Five proposed pathways were used to describe the metabolites found in rats: N-oxidation, oxidative N-debenzylation, pyrrolidinyl ring hydroxylation, phenyl hydroxylation and methyl or cyclohexyl hydroxylation. Two biotransformation pathways in dogs are proposed: N-oxidation and methyl or cyclohexyl ring hydroxylation.     

Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: Mosapride N-oxide and morpholine ring-opened mosapride by UPLC–ESI-MS/MS

The identification and structure elucidation of metabolites of mosapride, a selective gastroprokinetic agent, was investigated in rats. After oral administration, samples of rat urine, bile, feces and plasma were collected and analyzed by a selective UPLC–ESI-MS/MS method. Altogether 18 metabolites were detected and at least 15 metabolites were reported in rat for the first time. Two new metabolites, mosapride N-oxide in rat bile, urine and plasma, morpholine ring-opened mosapride in plasma and feces, were identified by comparison with the reference standards. One known major mammalian metabolite, des-p-fluorobenzyl mosapride, was also identified. The molecular structures of nine phase I metabolites and six phase II metabolites of mosapride were elucidated based on the characteristics of their protonated molecular ions, product ions and chromatographic retention times. The phase I metabolites were mainly transformed by four main metabolism pathways, dealkylation, N-oxidation, morpholine ring cleavage and hydroxylation, with dealkylation as the predominant metabolic pathway, while phase II metabolites were mainly formed by glucuronidation. The relatively comprehensive metabolic pathway of mosapride was proposed.     

UPLC-Q-Exactive Plus Orbitrap-MS鉴定桑色素在大鼠体内的代谢产物

目的 利用UPLC-Q-Exactive PlusSOrbitrap-MS技术对大鼠灌胃给予桑色素后体内的的主要代谢产物进行研究。方法 大鼠灌胃给予桑色素20 mg/kg后,分别收集血浆、尿液和粪便样品,采用超高压液相色谱串联高分辨质谱技术测定桑色素的体内代谢物。结果 根据一级质谱分子离子信息和二级质谱碎裂离子信息,在大鼠血浆和尿液中均发现2个葡萄糖醛酸代谢产物,在粪便中发现脱氢产物。结论 桑色素在大鼠体内的主要代谢途径为葡萄糖醛酸化反应。本研究初步阐明了桑色素在大鼠体内的代谢情况,为进一步药理作用机制研究提供依据。     

HPLC determination of polydatin in rat biological matrices: application to pharmacokinetic studies

A reversed-phase high-performance liquid chromatographic (RPHPLC) method has been developed for the determination of polydatin (PD) in rat plasma, bile, urine, feces and tissue homogenates using 2,3,5,4'-tetrahydroxychrysophenine-beta-d-glucoside as an internal standard. The sample pretreatment included deproteinization for plasma samples and a liquid-liquid extraction for bile, urine, feces and tissue homogenates. Separation was obtained on a C18 reversed-phase column with the mobile phase consisting of methanol and water (35:65 v/v). The flow rate was 1 ml/min and the effluent was monitored at 310 nm. The method showed good linearity over the concentration ranges employed for various matrices (r > 0.998). The quantification limits of PD in rat plasma, bile, urine, feces and tissue homogenates were 0.0251, 0.126, 0.025 microg/ml, 0.189 and 0.0378 microg/g, respectively. The accuracy and precision of the method were less than 12.0% for the various matrices. No interferences from endogenous substances were found. The method was successfully applied to study the pharmacokinetics of PD in rats after intravenous administration.